Analytical Data
-
Gene name
c-MPL/Thrombopoietin R
- Application
-
Species
Canine
-
Source
HEK293
-
Tag
C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
XP_038543911
-
Expression Region
Q22-W489
-
Protein Length
Partial
-
Molecular Weight
65-75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
c-MPL (the receptor for thrombopoietin) plays a crucial role in thrombopoiesis, the process of platelet production in the bone marrow. Thrombopoietin (TPO), a key regulator of this process, binds to c-MPL, initiating signaling pathways that promote the survival, proliferation, and differentiation of megakaryocytes, the progenitor cells for platelets. Dysfunctional c-MPL signaling is implicated in various hematological disorders, including immune thrombocytopenic purpura (ITP) and certain myeloproliferative neoplasms. As a result, research into c-MPL and TPO has gained significant attention, particularly in the development of therapeutic strategies aimed at modulating platelet production. Recombinant c-MPL/TPO receptor proteins are being studied for their potential to enhance platelet counts in patients with thrombocytopenia, enhance understanding of c-MPL signaling pathways, and explore novel treatment paradigms. These proteins serve not only as tools for basic research in hematology but also hold promise in clinical applications, including the design of new therapies for platelet disorders and the improvement of outcomes in patients undergoing chemotherapy or suffering from other conditions that lead to reduced platelet levels. The ongoing exploration of c-MPL/TPO interactions may lead to innovative approaches for managing bleeding disorders and improving the quality of life for affected patients.
